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Abstract
Background: Matrix metalloproteinases (MMPs) are thought to mediate cellular infiltration in
central nervous system (CNS) inflammation by cleaving extracellular matrix proteins associated
with the blood-brain barrier. The family of MMPs includes 23 proteinases, including six membrane
type-MMPs (MT-MMPs). Leukocyte infiltration is an integral part of the pathogenesis of
autoimmune inflammation in the CNS, as occurs in multiple sclerosis and its animal model
experimental autoimmune encephalomyelitis (EAE), as well as in the response to brain trauma and
injury. We have previously shown that gene expression of the majority of MMPs was upregulated
in the spinal cord of SJL mice with severe EAE induced by adoptive transfer of myelin basic protein-
reactive T cells, whereas four of the six MT-MMPs (MMP-15, 16, 17 and 24) were downregulated.
The two remaining MT-MMPs (MMP-14 and 25) were upregulated in whole tissue.
Methods: We used in vivo models of CNS inflammation and injury to study expression of MT-MMP
and cytokine mRNA by real-time RT-PCR. Expression was also assessed in microglia sorted from
CNS by flow cytometry, and in primary microglia cultures following treatment with IFNγ.
Results: We now confirm the expression pattern of MT-MMPs in the B6 mouse, independent of
effects of adjuvant. We further show expression of all the MT-MMPs, except MMP-24, in microglia.
Microglia isolated from mice with severe EAE showed statistically significant downregulation of
MMP-15, 17 and 25 and lack of increase in levels of other MT-MMPs. Downregulation of MT-MMPs
was also apparent following CNS injury. The pattern of regulation of MT-MMPs in
neuroinflammation showed no association with expression of the proinflammatory cytokines
TNFα, IL-1β, or IFNγ.
Conclusion: CNS inflammation and injury leads to downregulation in expression of the majority
of MT-MMPs. Microglia in EAE showed a general downregulation of MT-MMPs, and our findings
suggest that MT-MMP levels may inversely correlate with microglial reactivity.
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Background
Matrix metalloproteinases (MMPs) are proteinases impli-
cated in all diseases involving neuroinflammation,
including multiple sclerosis [1,2]. MMPs are thought to
facilitate cellular infiltration of the central nervous system
(CNS) by degrading extracellular proteins present in the
neurovascular unit, which is composed of endothelial
cells connected by tight junctions, and the glia limitans.
Inhibition of MMP activity with broad-spectrum synthetic
inhibitors alleviates symptoms of experimental autoim-
mune encephalomyelitis (EAE), an animal model of mul-
tiple sclerosis [3-6].
MT-MMPs are implicated in tumor development by pro-
moting angiogenesis and invasion across basement mem-
branes [7,8]. MT-MMPs are expressed in most cancer types
and are in many cases linked to malignant parameters
[9,10]. Several studies have demonstrated the importance
of MMPs in animal models of cancer, but so far MMP
inhibitors not been successful in clinical cancer trials [11].
This is likely because the broad-spectrum inhibitors used
failed to specifically target detrimental effects of MMPs,
and also inhibited beneficial effects [12]. This illustrates
the potential importance of understanding the differences
between individual MMPs in greater depth.
There are 23 MMPs identified in mice (including two
forms of MMP-1). Of these, six (MMP-14, 15, 16, 17, 24,
and 25) are referred to as membrane type-MMPs (MT-
MMPs) [13]. MMP-17 and 25 are glycosylphosphatidyli-
nositol (GPI)-anchored whereas the other four MT-MMPs
are type 1 transmembrane proteins with short cytoplasmic
domains of about 20 amino acids. Like secreted MMPs,
MT-MMPs can cleave extracellular matrix molecules, as
well as chemokines, cytokines and growth factors [9,14].
MT-MMPs are generally thought to play important regula-
tory roles because of their ability to cleave substrates in
the immediate vicinity of the cell membrane, where the
cleaved products can interact with cell-surface receptors.
In addition, MT-MMPs are known to cleave and activate
secreted MMPs, which was first described for activation of
MMP-2 by MMP-14 through interaction with tissue inhib-
itor of metalloproteinases-2 (TIMP-2) [15,16].
The particular roles and substrate specificities of MT-
MMPs have not been described in detail, and the role of
MT-MMPs in neuroinflammation is unclear. We previ-
ously showed that MT-MMPs are downregulated in spinal
cord of mice with adoptively transferred EAE (AT-EAE) at
peak disease, except for MMP-14 and MMP-25 which are
upregulated [17]. The downregulation of the majority of
MT-MMPs contrasts with the general upregulation of
secreted MMPs. Similar results were obtained by Weaver
et al. in actively induced EAE [18]. The functional conse-
quence of this specific pattern of MT-MMP expression is
unknown.
In this study, we describe MT-MMP expression by micro-
glia in EAE. We also investigate the relationship between
MT-MMP regulation, leukocyte infiltration, and expres-
sion of the proinflammatory cytokines TNFα, IL-1β, and
IFNγ in three models of neuroinflammation: EAE, pertus-
sis toxin (PTx)-induced parenchymal CNS infiltration in
transgenic (Tg) mice expressing the chemokine CCL2 in
the CNS, and after CNS injury induced by a cortical stab
lesion.
Materials and methods
Mice
Wild-type (WT) SJL/J (SJL) and C57BL/6J (B6) were
obtained from The Jackson Laboratory (Bar Harbor,
Maine, USA) or from Charles River Canada (St. Constant,
Quebec, Canada). Transgenic mice expressing the chem-
okine CCL2 under the control of a myelin basic protein
(MBP) promoter [19] were originally obtained from Bris-
tol-Myers Squibb (New Brunswick, New Jersey) and main-
tained as colonies at the Montreal Neurological Institute,
and at University of Southern Denmark. A colony of
IFNγR-/- mice on the SJL/J background was derived from
mice generously provided by Dr. David Willenborg (Can-
berra Hospital, Australia). For EAE, female mice 6–12
weeks old were used. Mice subjected to cortical lesion
were females weighing 20–25 grams. Animal breeding,
maintenance and all experimental protocols were per-
formed in accordance with Canadian Council for Animal
Care guidelines as approved by the McGill University Ani-
mal Care Committee, or protocols approved by the Dan-
ish Ethical Animal Care Committee
Actively induced EAE
B6 mice were immunized subcutaneously at the base of
the tail with 100 µl of an emulsion containing 100 µg
myelin oligodendrocyte glycoprotein (MOG)35–55 (Shel-
don Biotechnology, Montreal, Quebec, Canada) and 500
µg of Mycobacterium tuberculosis H37 RA (Difco, Detroit,
Michigan, USA) in Freund's incomplete adjuvant (Difco)
and boosted in the flanks 7 days later with the same emul-
sion. PTx (15 µg/kg) was administered intraperitoneally
on day 0 and 2. SJL mice were immunized subcutaneously
at the base of the tail with 100 µl of an emulsion contain-
ing 100 µg proteolipid protein (PLP)139–151 (Sheldon Bio-
technology) and 200 µg of Mycobacterium tuberculosis H37
RA (Difco) in Freund's incomplete adjuvant (Difco) and
boosted in the flanks 7 days later. Mice were weighed and
monitored daily for clinical signs of EAE, scored as: 1,
flacid tail; 2, hind limb weakness and poor righting abil-
ity; 3, one hind limb paralyzed; 4, both hind limbs para-
lyzed with or without forelimb paralysis; 5, moribund.Journal of Neuroinflammation 2007, 4:24 http://www.jneuroinflammation.com/content/4/1/24
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Adoptive transfer EAE
AT-EAE in SJL mice was induced by passive transfer of
MBP-reactive T cells as described previously [17]. AT-EAE
in B6 mice was induced by passive transfer of MOG35–55
reactive T cells. B6 mice were immunized as for active EAE
and lymph node cells were cultured in the presence of 10
µg/ml MOG35–55 (Sheldon Biotechnology) and 5 U/ml IL-
2 (Biosource, Nivelles, Belgium). Otherwise, culture con-
ditions were as described for SJL AT-EAE. 10 × 106 lym-
phoblasts were transferred into the tail vein. Recipient
mice received 15 µg/kg PTx ip on day 0 and 2 after trans-
fer, and were monitored and scored as described for active
EAE.
Administration of pertussis toxin to CCL2 Tg mice
PTx-induced parenchymal CNS infiltration in CCL2 Tg
has been described previously [20]. Briefly, PTx (10 µg/
kg) (Sigma, Oakville, Ontario, Canada) in Hank's bal-
anced salt solution (Invitrogen Life Technologies,
Carlsbad, California, USA) was injected intraperitoneally
at day 0. Mice were monitored and weighed daily until
sacrifice at day 5.
Cortical lesion
Under anesthesia, B6 mice were placed into a stereotactic
apparatus (Kopf, Tujunga, California, USA) for wireknife
transection of axons in the entorhinal cortex as previously
described [21]. This induces a cortical stab injury. Twenty-
four hours following surgery, mice were perfused with
phosphate buffered saline, the cortex was dissected, and
approximately 2 mm of tissue surrounding the wireknife
lesion was collected. For uninjured controls, the entorhi-
nal cortex was dissected from either the contralateral hem-
isphere of the brain or from unmanipulated mice.
Flow cytometry and cell isolation
Cells from whole CNS or isolated entorhinal cortex of
mice were prepared for flow cytometry as described
[17,21]. Flow cytometry data were analyzed using Cel-
lQuest Pro software (BD Biosciences, San Jose, California,
USA).
Quantitative real-time RT-PCR
RNA from whole tissue and sorted cells was purified using
Trizol RNA isolation reagent (Invitrogen Life Technolo-
gies) according to the manufacturer's protocol. RNA (3
µg) from each tissue sample was incubated with M-MLV
reverse transcriptase (RT) (Invitrogen Life Technologies)
according to the manufacturer's protocol using random
hexamer primers. RNA from sorted cells was incubated
with SuperScript II RT (Invitrogen Life Technologies)
according to the manufacturer's protocol using random
hexamer primers. Quantitative real-time PCR was done
using ABI Prism 7000 or 7300 Sequence Detection Sys-
tems (Applied Biosystems, Foster City, California, USA).
Probe and primer sequences for MT-MMPs [22], IFNγ
[23], and TNFα and IL-1β [24] were described previously.
Expression of 18S rRNA (primers and probes from
Applied Biosystems) in cDNA samples diluted 1/1000
was used to control for differences in the extraction and
reverse transcription of total RNA. Each reaction was per-
formed in 25 µl with 50% TaqMan 2× PCR Master Mix
(Applied Biosystems), 100 nM each of the forward and
reverse primer, and 200 nM of probe. Conditions for the
PCR were 2 min at 50°C, 10 min at 95°C, and then 40
cycles, each consisting of 15 s at 95°C, and 1 min at 60°C.
Arbitrary cDNA values of individual samples were deter-
mined using standard curves obtained from a 4-fold serial
dilution of a reference cDNA sample. Relative expression
values were calculated by dividing the expression level of
the target gene by the expression level of 18S rRNA.
Isolation and culturing of microglia
Female SJL WT or IFNγR-/- mice (8–10 weeks old) were
perfused with 20 ml ice-cold phophate buffered saline,
then brains and spinal cords were dissected and collected
in Hank's balanced salt solution. The tissue was dissoci-
ated through a 70 µm cell strainer (BD Biosciences
Pharmingen) and suspended in 70% isotonic Percoll
(Amersham Biosciences, Baie d'Urfe, Quebec, Canada).
Myelin was removed after centrifugation through a Percoll
gradient, and cells were collected at the interface between
30 and 37% Percoll. Cells were washed and resuspended
in RPMI 1640 (Gibco, Burlington, Ontario, Canada) sup-
plemented with 10% FCS (Sigma), 50 µM β-mercaptoeth-
anol (Sigma), 2 mM L-glutamine (Gibco), 100 U/ml
penicillin and 100 µg/ml streptomycin (Gibco). Finally,
cells were diluted to 1 × 106 cells/ml and plated in a 96
well culture plate (Nunc, Roskilde, Denmark) at a density
of 2 × 105 cells per well. Approximately 2.5 × 105 microglia
were obtained per mouse. An aliquot of cells stained for
verification of CD45dim CD11b+ microglia, showed that
purity was ≥ 94%. Microglia were left overnight to settle
and thereafter treated with mouse recombinant IFNγ
(Sigma) for 16 hours. The supernatant was removed and
microglia were lysed in Trizol for RNA isolation.
Statistical analysis
One-way ANOVAs with Bonferroni's post test, or two-
tailed unpaired t-tests were applied to analyze results
using the GraphPad Prism software (GraphPad Software
Inc., San Diego, California, USA). p ≤ 0.05 was considered
significant. Error bars represent standard error of the
mean.
Results
MT-MMP expression in EAE
We previously found that MMP-15, 16, 17 and 24 are
downregulated in spinal cord of SJL mice with MBP-
induced AT-EAE, whereas the remaining two MT-MMPsJournal of Neuroinflammation 2007, 4:24 http://www.jneuroinflammation.com/content/4/1/24
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(MMP-14 and 25) are upregulated [17]. The expression of
all six MT-MMPs has now been studied in both actively
induced and adoptively transferred MOG35–55 EAE in B6
mice with severe (grade 4) disease (Fig. 1). Some differ-
ences in fold regulation were observed compared to AT-
EAE in SJL mice, but statistically significant downregula-
tion of MMP-15, 16, 17 and 24 was observed in both
models, as well as upregulation of MMP-14 and 25. Simi-
lar results for actively induced EAE in B6 mice have been
reported previously [18]. Taken together, this shows that
the pattern of MT-MMP regulation in severe EAE is inde-
pendent of mouse strain, myelin antigen, and use of adju-
vant in disease induction.
Microglial MT-MMP expression in EAE
Macrophages are known to be major producers of MMPs
[17,25]. Microglia share a common myeloid lineage with
macrophages, and are considered to be CNS-resident mac-
rophages. Human microglia express a wide spectrum of
MMP transcripts, many of which are regulated upon acti-
vation in vitro [26]. We investigated microglial MT-MMP
expression at peak disease (Fig. 2). Microglia were defined
as CD45dim CD11b+ cells and sorted using flow cytometry.
We observed a statistically significant downregulation of
MMP-15, 17 and 25 by microglia in EAE (Fig. 2B, D and
2E) compared to control microglia from unmanipulated
mice. This confirms results for MMP-15 published previ-
ously [17]. Microglial expression of MMP-14 and 16 (Fig.
2A and 2C) were not significantly altered in EAE. MMP-24
was not expressed by sorted microglia.
MT-MMP mRNA expression in microglia sorted from CNS Figure 2
MT-MMP mRNA expression in microglia sorted from 
CNS. Microglia were sorted from whole CNS preparations 
based on flow cytometric detection of the surface markers 
CD45dim CD11b+. Values on the Y-axis are relative to 
expression of 18S rRNA, and normalized to the expression 
level of the unmanipulated microglia. The values are arbitrary 
and cannot be compared between panels. n = at least 4 in 
each group; NS: not significant; Unm.: unmanipulated; *: p ≤ 
0.05.
MT-MMP gene expression in active and AT-EAE in B6 mice Figure 1
MT-MMP gene expression in active and AT-EAE in 
B6 mice. Gene expression levels of MT-MMPs in spinal cord 
from unmanipulated B6 mice and mice with severe (grade 4) 
EAE were measured by real-time PCR. EAE was induced 
either by immunization with MOG35–55 in CFA (active) or 
adoptive transfer of MOG35–55 specific T cells (AT-EAE). Val-
ues on the Y-axis are relative to expression of 18S rRNA, 
and normalized to the expression level of the unmanipulated 
group. The values are arbitrary and cannot be compared 
between panels. n = 4 or 5. Unm.: unmanipulated; Act.: 
active; *: p ≤ 0.05.Journal of Neuroinflammation 2007, 4:24 http://www.jneuroinflammation.com/content/4/1/24
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Expression of MT-MMPs is unchanged by PTx-induced 
parenchymal infiltration in CCL2 Tg mice
To investigate the relationship between the general proc-
ess of leukocyte infiltration of the CNS, and the pattern of
MT-MMP expression, we used a model of neuroinflamma-
tion that we have previously described [20]. Leukocytes
spontaneously accumulate in the perivascular space in the
CNS of transgenic mice which express the chemokine
CCL2 under control of a truncated MBP promoter [19].
Systemic administration of PTx causes parenchymal infil-
tration in CCL2 Tg mice [20]. Expression in brain was not
significantly altered for any of the MT-MMPs following
administration of PTx to CCL2 Tg mice (data not shown).
In contrast to the MT-MMPs investigated in this study, we
previously found that secreted MMPs were upregulated
upon PTx injection in CCL2 Tg mice [20], suggesting
involvement of MMPs in leukocyte migration, while
emphasizing the distinction between secreted MMPs and
MT-MMPs.
MMP-15, 17 and 25 are downregulated after CNS stab 
injury
In contrast to the CCL2 Tg mouse, which represents chem-
okine-driven leukocyte entry to the CNS, cortical stab
injury induces both leukocyte infiltration and glial activa-
tion [27,28]. We studied MT-MMP expression following a
stab lesion to the entorhinal cortex. Twenty-four hours
after stab lesion in the cortex, we observed considerable
infiltration of CD45high cells (Fig. 3). The majority of the
infiltrating cells were macrophages or granulocytes,
defined as CD45high CD11b+ (Fig. 3A, upper right quad-
rants), and a smaller proportion were T cells defined as
CD45high TCRβ+ (Fig. 3B, inserted boxes). MMP-15, 17
and 25 were statistically significantly downregulated fol-
lowing stab lesion, whereas no significant change in
expression of MMP-14, 16 and 24 was noted (Fig. 4A–F).
MT-MMP regulation in neuroinflammation does not 
relate to expression of the proinflammatory cytokines 
TNFα, IL-1β, and IFNγ
Expression of MT-MMPs can be regulated by growth fac-
tors and cytokines [13,29]. We considered the proinflam-
matory cytokines TNFα, IL-1β, and IFNγ as possible
candidates for regulators of MT-MMP expression. Both
TNFα and IL-1β were upregulated in EAE and after cortical
lesion (Fig. 5), as well as after PTx-induced parenchymal
infiltration in CCL2 Tg mice [20]. By contrast, IFNγ, which
is absent from unmanipulated CNS, was only upregulated
in EAE and not after cortical lesion (Fig. 5C). Unmanipu-
lated CCL2 Tg mice showed a basal level of IFNγ expres-
sion in brain, but this was unchanged by systemic
administration of PTx (data not shown). Since TNFα and
IL-1β showed similar regulation in all three in vivo models
used, they seemed unlikely candidates to account for the
differences seen in MT-MMP expression. We therefore
asked whether IFNγ played a regulatory role with respect
to MT-MMP expression. This was tested by inducing EAE
in IFNγ-/- mice, and assessing MT-MMP expression in the
spinal cord using real-time PCR. However, when IFNγ-/-
mice with grade 4 EAE were compared to unmanipulated
WT mice, we observed the same pattern of MT-MMP
expression as in WT mice with grade 4 EAE (data not
shown). Thus, absence of IFNγ did not lead to different
regulation of MT-MMP expression in EAE spinal cord.
IFNγ does not regulate microglial MT-MMP expression in 
vitro
To directly test if IFNγ regulates MT-MMP expression by
microglia, we isolated microglia from CNS of adult WT
and IFNγR-/- SJL mice and pooled cells from each group.
Cell preparations were determined by FACS to contain
94% CD45dim CD11b+ microglia. The microglia were then
treated with varying concentrations of recombinant IFNγ.
WT microglia responded to IFNγ by upregulating TNFα,
whereas IFNγR-/- microglia did not (Fig. 6A). However,
no statistically significant change in expression by micro-
glia of MMP-15 (Fig. 6B), or any other MT-MMP (data not
shown) was observed in response to IFNγ treatment.
Discussion
The downregulation of certain MT-MMPs in neuroinflam-
mation does not correspond well with a simple interpre-
tation of MMPs solely as pro-inflammatory mediators.
Flow cytometric analysis of cells in the entorhinal cortex fol- lowing lesion Figure 3
Flow cytometric analysis of cells in the entorhinal 
cortex following lesion. A: Flow cytometry profiles show-
ing CD45high CD11b+ macrophages and granulocytes (upper 
right quadrants) in uninjured control entorhinal cortex (left 
panel) and 24 hours after stab injury (right panel) in B6 mice. 
B: Equivalent analysis of CD45high TCRβ T cells (inserted 
boxes). The result shown for one mouse in each group is 
representative of four mice in both groups.Journal of Neuroinflammation 2007, 4:24 http://www.jneuroinflammation.com/content/4/1/24
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However, given that the specific substrates of individual
MT-MMPs remain ill-defined, it is not possible to clearly
explain the consequences of the downregulation. One
may speculate that microglia downregulate certain MT-
MMPs in the process of activation, such as is the case for
the innate immune receptor TREM-2 [30,31]. The func-
tional consequence of upregulation of MMP-14, MMP-25
or secreted MMPs in neuroinflammation can be inter-
preted simply to reflect expression of proteinases by infil-
Gene expression of cytokines after brain stab lesion and in  EAE Figure 5
Gene expression of cytokines after brain stab lesion 
and in EAE. Real-time PCR analysis of cytokine expression 
in entorhinal cortex (left side of graphs) and in spinal cord 
(right side). Entorhinal cortex samples were from B6 mice 24 
after stab lesion, or from control entorhinal cortex. Spinal 
cord samples were from B6 mice with grade 4 AT-EAE 
induced by MOG35–55 specific T cells, or from unmanipulated 
controls. IFNγ was only detected in one of 5 stab samples 
(Panel C). Values on the Y-axis are relative to expression of 
18S rRNA, and normalized to the expression level of the 
control entorhinal cortex group (except for IFNγ). The val-
ues are arbitrary and cannot be compared between panels. n 
= 4–6. ND: not detected; Unm.: unmanipulated; C: control; 
NS: not significant; *: p ≤ 0.05.
Gene expression of MT-MMPs after brain stab lesion Figure 4
Gene expression of MT-MMPs after brain stab lesion. 
Real-time PCR analysis of MT-MMP expression in entorhinal 
cortex. Samples were from B6 mice 24 after stab lesion, or 
from control entorhinal cortex tissue. Values on the Y-axis 
are relative to expression of 18S rRNA, and normalized to 
the expression level of the control group. The values are 
arbitrary and cannot be compared between panels. Signifi-
cance of comparisons was determined using a two-tailed t-
test. n = 6 for C, and 5 for Stab. C: control; NS: not signifi-
cant; *: p ≤ 0.05.Journal of Neuroinflammation 2007, 4:24 http://www.jneuroinflammation.com/content/4/1/24
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trating cells, enabling them to cross the blood-brain
barrier into the CNS by cleaving extracellular matrix pro-
teins. This is most likely not the complete explanation,
since MMPs have many other substrates than matrix pro-
teins, and MMPs are likely also involved in regulation of
the inflammatory process by cleaving bioactive molecules
[14,32].
We confirmed that the previously established pattern of
MT-MMP regulation in EAE spinal cord: downregulation
of MMP-15, 16, 17 and 24, and upregulation of MMP-14
and 25 is independent of mouse strain, myelin antigen,
and use of adjuvant. In microglia sorted from the CNS of
mice with EAE, MMP-15, 17 and 25 were downregulated.
This corresponds with the change in whole spinal cord for
MMP-15 and 17. For MMP-25, the change on the whole
spinal cord level was in the opposite direction, which
illustrates that changes in gene expression in individual
cell types can be masked by changes at the whole tissue
level. In this case, the discrepancy is likely due to infiltra-
tion of MMP-25 expressing leukocytes. MMP-25 is also
known as leukolysin and is expressed by neutrophils
[26,33].
Some caution must be exercised in interpreting results
that show a small downregulation of mRNA at the whole
tissue level in an organ that is undergoing infiltration. We
have previously determined the proportion of CD45high
infiltrating cells at peak AT-EAE in SJL mice to be 34% in
CNS isolates [17]. If such infiltrating cells did not express
a particular gene which is expressed by endogenous cells
in the unmanipulated CNS, then the influx of these cells
alone would lead to an overall downregulation in expres-
sion of that gene per cell at the whole tissue level, even
though the expression level in individual resident cells did
not change. We analyzed microglia from both unmanipu-
lated mice and mice with EAE for direct comparison of
this cell type in a disease state with the normal state.
In EAE spinal cord, we found two up and four downregu-
lated MT-MMPs. In the injured entorhinal cortex, we
found that MMP-15, 17 and 25 were downregulated, with
no change of the remaining MT-MMPs. After PTx-induced
parenchymal CNS infiltration in CCL2 Tg mice, we noted
no change in MT-MMP expression. The different regula-
tion of MT-MMP expression in these three in vivo models
of neuroinflammation could potentially be due to differ-
ent involvement of glial responses and cytokine levels. We
investigated whether regulation of proinflammatory
cytokines could account for the differences seen in MT-
MMP expression. It was previously shown that a stab
injury in the cortex lead to induction of IL-1β and TNFα,
but not IFNγ[34], and we confirmed this. Comparing the
models, TNFα and IL-1β were both significantly upregu-
lated in all three models (Fig. 5A and 5B; and), whereas
effects on IFNγ levels differed: IFNγ was absent from
unmanipulated CNS, but upregulated in EAE; unmanipu-
lated CCL2 Tg mice showed a basal level of IFNγ, which
was unchanged following administration of PTx; and
IFNγ was absent, except for a low level in one out of five
TNFα and MMP-15 expression by microglia stimulated in  vitro Figure 6
TNFα and MMP-15 expression by microglia stimu-
lated in vitro. Microglia isolated from 12 WT and 8 IFNγR-/
- mice were pooled separately and dispersed at 2 × 105 cells 
per well. Cultured microglia were stimulated with IFNγ in 
media at varying concentrations, or media only as control. 
Each bar graph represents results from three identically 
treated wells. Values on the Y-axis are relative to expression 
of 18S rRNA, and normalized to the expression level of the 
each control group, respectively. The values are arbitrary 
and cannot be compared between panels. U: units; NS: not 
significant; *: p ≤ 0.05.Journal of Neuroinflammation 2007, 4:24 http://www.jneuroinflammation.com/content/4/1/24
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samples, following cortical lesion. However, in vivo exper-
iments in IFNγ-/- mice revealed that absence of IFNγ did
not change the regulation of MT-MMP expression in EAE.
Likewise, IFNγ did not change MT-MMP expression by
microglia in vitro.
Conclusion
We describe a general trend to downregulation of MT-
MMPs across in vivo models of neuroinflammation. The
downregulation of MT-MMPs was generally reflected in
microglia, and might be part of an intrinsic component in
the microglial response to inflammation and injury. Our
findings suggest that downregulation of MT-MMPs occur
independently of expression of the proinflammatory
cytokines TNFα, IL-1β, and IFNγ.
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